The following information is intended for use by viewers in the United States.

Synagis^® (palivizumab) is the only monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) to help prevent an infectious disease. Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.
To learn more about Synagis, including Important Safety & Prescribing Information, click here. 

Ethyol^® is a selective cytoprotective agent used to reduce certain toxicities associated with cancer chemotherapy and radiotherapy.
To learn more about Ethyol, including Important Safety & Prescribing Information, click here. 

FluMist^® (Influenza Virus Vaccine Live, Intranasal) is the first and only nasal spray flu vaccine approved in the U.S. to help prevent influenza and is indicated for the active immunization of eligible individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
To learn more about FluMist, including Important Safety & Prescribing Information, click here. 

View R&D Pipeline